Filing Analysis
Tenaya Therapeutics reported the results of its May 27, 2026, annual meeting of stockholders. The company successfully elected Class II directors, ratified Deloitte & Touche LLP as its auditor, and approved an amended and restated 2021 Equity Incentive Plan.
🚩 Red Flags
- The approval of the Equity Incentive Plan (Proposal 3) saw a notable amount of 'Against' votes (20,575,701) compared to the 'For' votes (67,356,607), indicating some shareholder resistance to the dilution.
📋 Key Facts
- Stockholders approved the Amended and Restated 2021 Equity Incentive Plan on May 27, 2026.
- The incentive plan update includes a one-time increase of 6,509,966 shares (approx. 3% of outstanding shares).
- The 'evergreen' provision was amended to remove the 4 million share annual limit, keeping the increase at 4% of outstanding shares.
- Class II Directors Amy Burroughs, Karah Parschauer, and Catherine Stehman-Breen were elected to serve until 2029.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
Tenaya Therapeutics announced its financial results for the first quarter ended March 31, 2026. The filing is a routine disclosure of quarterly performance and includes the earnings press release as an exhibit.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026
- Filing dated May 6, 2026
- Triggered Item 2.02 (Results of Operations and Financial Condition)
- Exhibit 99.1 contains the full press release
Tenaya Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The filing serves as a formal announcement of these results via a press release attached as Exhibit 99.1.
📋 Key Facts
- The report was filed on March 11, 2026.
- The financial results cover the fiscal quarter and full year ended December 31, 2025.
- The disclosure was made under Item 2.02 (Results of Operations and Financial Condition).
- The company is classified as an emerging growth company.
Tenaya Therapeutics entered into a multi-target research collaboration with Alnylam Pharmaceuticals to discover and validate novel gene targets for cardiovascular disease. The deal includes an upfront payment of up to $10 million and potential future milestones totaling $1.13 billion.
🚩 Red Flags
- Alnylam may unilaterally terminate the agreement in its entirety for any or no reason.
- The upfront payment is relatively small ($10M) compared to the $1.13B headline milestone figure, which is highly contingent on long-term success.
📋 Key Facts
- Agreement signed on March 4, 2026, for a 24-month initial research collaboration period.
- Tenaya and Alnylam will nominate an aggregate of 15 targets for validation.
- Tenaya receives an upfront payment of up to $10.0 million, subject to $500,000 reductions for certain targets not advanced.
- Tenaya is eligible for up to $1.13 billion in aggregate development, regulatory, and sales-based milestones.
- Alnylam will reimburse Tenaya for full-time employees (FTEs) and out-of-pocket costs during the validation phase.
- Alnylam assumes sole responsibility for development, manufacturing, and commercialization after the validation phase.